Skip to main

Impact case study database

The impact case study database allows you to browse and search for impact case studies submitted to the REF 2021. Use the search and filters below to find the impact case studies you are looking for.
Impact case study database FAQs
Download all impact case studies (spreadsheet)
Download all impact case studies (spreadsheet) (generating)
Download all impact case study tags (spreadsheet)
Download all impact case study tags (spreadsheet) (generating)
Back

Rucaparib targeted therapy for a range of cancers characterised by homologous repair deficiency

Download case study PDF
Submitting institution
University of Newcastle upon Tyne
Unit of assessment
1 - Clinical Medicine
Summary impact type
Health
Request cross-referral to
-
Is this case study continued from a case study submitted in 2014?
Yes
Underpinning research subjects
  • Clinical Sciences
  • Oncology And Carcinogenesis
  • Pharmacology And Pharmaceutical Sciences

1. Summary of the impact

2. Underpinning research

3. References to the research

4. Details of the impact

5. Sources to corroborate the impact

Additional contextual information

Grant funding

Grant number Value of grant
BH163218 £289,163
N/A £20,146
30015.088.033/PA/DB £49,958
JAG/ML/0614 £49,896
113353 £182,565
N/A £48,860
N/A £146,839
C9380/A7810 £125,000
06-031 £77,510
N/A £131,280
C5201/A6710 £105,000
JAG/ML/1211 £34,251
Countries
  • UK
  • US
Formal partners
  • Professor Iain McNeish, Glasgow University
Funding programmes
  • NEOCATS – Northern nEoadjuvant Ovarian CAncer Translational Study
  • Pre-clinical work to support CRUK Combinations Alliance trial application to combine Rucaparib and VS5584
  • Improving the response rate in ovarian cancer by compromising DNA repair
  • Determination of Homologous Recombination Repair (HRR) function in malignant ascites: optimisation and validation for multicentre stratified medicine trials
  • Pre-clinical work-plan and PD assays for BMN673 clinical trial
  • Determining the duration of PARP inhibition
  • Therapeutic potential of PARP inhibitors in cancers defective in BRCA1, BRCA2 or other defects contributing to a “BRCAness” phenotype
  • Clinical Fellowship to Support the Phase II Proof of Principle Study of the Potent PARP-1 Inhibitor, AG014699, in known Carriers of BRCA1 and BRCA 2
  • Poly(ADP-ribose) polymerase pharmacogenetics and expression analysis in patients receiving anticancer therapy
  • Proposal for addition of pharmacodynamic sampling to AG014699/temozolomide phase II study
  • Investigation of the role of poly(ADP-ribose) polymerase (PARP) inhibition in topoisomerase I (topo I) poison-induced cytotoxicity
  • Determination of HR status in Pleural Effusions
Global research identifiers
  • N/A
  • 431052.1
  • 480530.a
  • N/A
  • 422932.c
  • 418566.8
  • 418566.8
  • 11485.39
  • 453093.8
  • 418566.8
  • 11485.39
  • N/A
Name of funders
  • Newcastle Healthcare Charity
  • Verastem
  • JGW Patterson Foundation
  • Newcastle Health Care Charity and the Newcastle upon Tyne Hospitals NHS Charity
  • BioMarin
  • Pfizer
  • Pfizer
  • Cancer Research UK
  • American Institute for Cancer Research, now Worldwide Cancer Research
  • Pfizer
  • Cancer Research UK
  • Newcastle upon Tyne NHS Foundation Trust Flexibility and Sustainability Funding
Researcher ORCIDs
  • 0000-0003-1369-1843
  • 0000-0001-6676-9224
  • 0000-0003-0107-1444
  • 0000-0001-5160-3600
  • 0000-0003-3999-4850
  • 0000-0002-8920-9286
  • 0000-0002-8897-0161